University System of Maryland

The United States of America, as Represented by the Secretary, Department of Health and Human Services

Stefanie N Vogel

Alessio Fasano

Frank Cuttitta

Philip R DeShong

Daniel C Stein

Katharina Richard

Lenea Stocker

Ruiliang Lu

Zachary J Roberts

Jorge Blanco

Julie Brownley

Karen Lammers

Kari Ann Shirey

The disclosure relates to compositions, pharmaceutical compositions, vaccines, and methods of making and using the same. The compositions of the disclosure are useful to stimulate an antigen-specific immune response and, in some embodiments, a protective immune response in an animal after challenge to pathogens. The compositions of the disclosure are also useful for treatment and prevention of disease in a subject such as cancer.

Compositions and vaccines comprising vesicles and methods of using the same

The present invention is directed to methods for treating orthomyxovirus infections comprising administering to a subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

Administration of eritoran or pharmaceutically acceptable salts thereof to treat orthomyxovirus infections

The invention relates to the areas of therapeutics, pharmaceuticals, drug discovery, and immunotherapy. More specifically, the present invention relates to methods of stimulating the immune system through the administration of flavone acetic acid [FAA] analogs, and in particular, the flavone acetic acid analog, 5,6-dimethylxanthenone-4-acetic acid (DMXAA) so as to comprise an antimicrobial therapeutic agent for the treatment of viral infections of DNA and RNA viruses in humans and non-human animals. The invention is especially suitable for use in a process of treating and preventing infection by, for example, rhinoviruses, enteroviruses, and influenza viruses.

Use of 5,6-dimethylxanthenone-4-acetic acid as an antiviral agent

Agonist polypeptide of a receptor protein has been identified. The agonist can be used to facilitate drug and antigen absorption. Suitable routes of administration include oral, nasal, transdermal, and intravenous. Pharmaceutical formulations may comprise a therapeutic agent or an immunogenic agent in combination with the agonist polypeptide.

Agonist polypeptide of receptor for ZOT and zonulin

CXCR3 is identified as a physiological receptor for Gliadin. Assays for determining modulators of CXCR3 signaling are provided. Fragments of gliadin which function as inhibitors of CXCR3 signaling can be determined. Methods for treating diseases relating to gluten and/or autoimmunity by targeting CXCR3 are provided. Such diseases include celiac disease, gluten sensitivity, gluten allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, inflammatory bowel diseases, systemic lupus erythematosus, psoriasis, scleroderma, and autoimmune thyroid diseases.

Methods for screening for modulators of CXCR3 signaling

Agonist polypeptide of receptor for Zot and Zonulin

Growing community of inventors

Columbia, MD, United States of America

Stefanie N Vogel